Consejo Superior de Investigaciones Científicas (CSIC) has synthesized antiviral compounds reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Syndax Pharmaceuticals Inc. has disclosed extended purine tricyclic and bicyclic nucleosides as prodrugs reported to be useful for the treatment of viral infections.
Decoy Therapeutics Inc. has announced that a series of antiviral drug candidates previously designed by its Imp3act platform to be broadly effective against viruses of the paramyxoviridae family have also shown promising in silico activity against measles and Nipah viruses. The candidates were previously shown to be active in vitro against respiratory syncytial virus and human parainfluenza virus 3.
Orthogon Therapeutics LLC has closed an oversubscribed financing round, with funding to be used to accelerate the development of its first-in-class treatments for managing BK virus reactivation in transplant patients.
Researchers from Emory University, the U.S. CDC and collaborators have identified a broad-spectrum antiviral agent able to combat highly pathogenic arenaviruses. The compound, a ribonucleoside analogue that acts through RdRp inhibition, exhibited a good pharmacokinetic profile, oral bioavailability and tissue distribution in guinea pigs, while protecting animals from lethal challenges with Lassa and Junín viruses, even at very low doses.
Researchers from Emory University, the U.S. CDC and collaborators have identified a broad-spectrum antiviral agent able to combat highly pathogenic arenaviruses. The compound, a ribonucleoside analogue that acts through RdRp inhibition, exhibited a good pharmacokinetic profile, oral bioavailability and tissue distribution in guinea pigs, while protecting animals from lethal challenges with Lassa and Junín viruses, even at very low doses.
Epigenic Therapeutics Inc. has received clinical trial application (CTA) approval from the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) and the Health and Disability Ethics Committees (HDEC) to initiate a clinical trial for EPI-003, an investigational, liver-targeting antiviral therapy for chronic hepatitis B virus (HBV) infection.
Currently, there are no specific antiviral drugs available for treating hepatitis E virus (HEV) infection, which represents a global health burden, causing acute viral hepatitis with varying clinical outcomes.
Tonix Pharmaceuticals Holding Corp. has entered into an artificial Intelligence and machine learning research collaboration with X-Chem Inc. to accelerate development of Tonix’s oral broad-spectrum antivirals for medical countermeasures.
